证券日报网讯 1月22日，西点药业发布公告称，公司于近日收到国家药品监督管理局签发的硫酸氨基葡 萄糖胶囊《药品注册证书》。该产品的获批进一步丰富了公司的产品线，有助于提升公司产品的市场竞 争力。 （文章来源：证券日报） ...

Group 1 - The company plans to repurchase shares through a centralized bidding method, with a total amount between 25 million and 50 million yuan, and a maximum repurchase price of 42.00 yuan per share, which is 33.59% higher than the current price of 31.44 yuan [1] - The stock price of the company has increased by 10.16% year-to-date [1] - The company specializes in the research, production, and sales of chemical pharmaceutical raw materials and formulations, with main revenue sources being 54.15% from risperidone orally disintegrating tablets and 45.13% from compound ferrous sulfate folic acid tablets [1] Group 2 - As of September 30, the number of shareholders is 7,863, a decrease of 2.91% from the previous period, while the average circulating shares per person increased by 2.97% to 7,426 shares [2] - For the period from January to September 2025, the company reported operating revenue of 189 million yuan, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 33.14 million yuan, down 2.70% year-on-year [2] - The company has distributed a total of 63.34 million yuan in dividends since its A-share listing, with 52.83 million yuan distributed over the past three years [3]

北京商报讯（记者 丁宁）1月22日晚间，西点药业（301130）发布公告称，基于对公司未来发展前景的 信心和对公司长期价值的高度认可，为维护全体投资者利益，增强投资者对公司的信心，进一步健全公 司激励机制，充分调动公司员工的积极性，促进公司可持续发展，经综合考虑公司发展战略、经营情 况、财务状况以及未来的盈利能力等因素，公司拟使用自有资金和/或自筹资金通过集中竞价交易方式 回购公司已发行的人民币普通股（A股）股票，回购的股份将在未来适宜时机用于员工持股计划或股权 激励。回购股份的资金总额不低于2500万元（含），不超过5000万元（含）。 ...

格隆汇1月22日丨西点药业(301130.SZ)公布，第八届董事会第十四次会议，审议通过了《关于拟设立全 资子公司的议案》，同意公司拟使用自有资金200万元人民币在吉林省磐石市投资设立全资子公司西点 大药房有限公司（暂定名，最终以市场监督管理部门核准结果为准，简称"西点大药房"），并授权公司 管理层办理西点大药房的设立登记事宜。授权有效期自董事会审议通过之日起至工商变更登记及章程备 案办理完毕之日止。 ...

格隆汇1月22日丨西点药业(301130.SZ)公布，拟回购股份的资金总额不低于人民币2,500万元，不超过人 民币5,000万元，回购股份的价格不超过人民币42.00元/股，用于实施员工持股计划或股权激励。 ...

西点药业（301130）(301130.SZ)公告，公司拟回购公司股份用于实施员工持股计划或股权激励。回购 股份的资金总额不低于2500万元(含)，不超过5000万元(含)。回购股份的价格不超过42.00元/股(含)。回 购股份的实施期限自公司董事会审议通过本次回购股份方案之日起12个月内 ...

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

Core Viewpoint - The company plans to establish a wholly-owned subsidiary, Xidian Pharmacy Co., Ltd., with an investment of 2 million RMB to enhance market expansion and business development [1] Group 1 - The board of directors will hold the 14th meeting of the 8th session on January 22, 2026, to review the proposal for the establishment of the subsidiary [1] - The new subsidiary will primarily engage in drug retail, the operation of Class III medical devices, and the sale of disinfectant equipment [1] - This investment aligns with the company's strategic development plan and aims to facilitate market expansion [1]

南财智讯1月22日电，西点药业公告，公司"草酸艾司西酞普兰原料药生产项目"计划投资5,350.19万元， 资金来源于首次公开发行股票的募集资金，用于原料药生产建设。由于宗地内原有污水管线、高压入户 线及外部化工管线影响施工，导致规划设计、土建建设及设备安装延迟，项目整体进度不及预期，公司 决定将该项目预定可使用状态时间由2026年2月23日延期至2026年6月30日。本次延期不涉及项目实施主 体、建设内容、投资规模及资金用途变更，不会对公司主营业务和整体募资安排造成实质性影响，亦不 改变公司既定战略，有利于提高募集资金使用效率。公司将继续加强项目管理，确保按期完成建设。 ...

人民财讯1月22日电，西点药业（301130）1月22日公告，公司拟以2500万元—5000万元回购股份，用于 实施员工持股计划或股权激励，回购价格不超过42元/股。 ...